PI4 - A Trial Assessing Metformin to Prolong Gestation in Preterm Preeclampsia
Status:
Recruiting
Trial end date:
2029-07-31
Target enrollment:
Participant gender:
Summary
Preterm preeclampsia is a severe condition for both the mother and the fetus. Currently, the
only treatment available to stop disease progression is termination/delivery of the fetus and
placenta. Therefore, preterm preeclampsia carries the highest rates of neonatal morbidity and
mortality due to iatrogenic preterm birth. There is evidence suggesting metformin, a drug
commonly used to treat diabetes in and outside pregnancy, may be able to counter the
pathophysiology of preeclampsia, raising the possibility that it could be used to treat the
condition. This multi centre double blind randomised controlled trial aims to investigate if
metformin can prolong gestation, lower neonatal length of stay and increase birthweight in a
Swedish setting.